- Health Canada approved TLANDO (testosterone undecanoate) capsules for TRT in adult males with hypogonadism.
- Verity Pharmaceuticals holds exclusive North American rights under a January 2024 license agreement.
- Canadian launch planned by end of 2026.
- Over 700,000 TRT prescriptions written annually in Canada; ~50% covered by private insurance.
- TLANDO is an oral therapy with fixed dose, no titration required.
- Health Canada approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy in adult males with hypogonadism. The approval was obtained by Lipocine's licensing partner Verity Pharmaceuticals, which holds exclusive North American commercial rights. Verity plans to launch in Canada by end of 2026.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card